LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG

Recruiting now · Not applicable

Conditions studied: Metastatic Lung Cancer

In brief

Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible. Presence of a mutation after NGS analysis is required for ctDNA follow-up.

Key facts

Study ID

NCT04790682

Run by

Institut Curie

People needed

300

Starts

2021-05-22

Expected to finish

2030-06-03

Last updated by the study team

2025-09-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically-proven NSCLC.
• Age ≥ 18 years.
• Advanced or metastatic stage IV.
• Treatment-naïve patient.
• Eligibility to first-line treatment with immune checkpoint inhibitor.
• Measurable disease according to RECIST 1.1 criteria on CT-Scan.
• Availability of expression of PD-L1 at immunohistochemistry analysis of the tumor biopsy.
• No ALK or EGFR gene alteration.
• Availability of tumor tissue for NGS analysis (7 slides).
• PS 0 or 1.
• Signed informed consent of the patient.

You may not qualify if…

• No social security affiliation.
• Person under legal protection.
• Pregnant and breastfeeding women.
• Patients can participate to another clinical trial that is not modifying immunotherapy or immunotherapy/chemotherapy treatment nor study follow-up ; after investigator's information

Where it is running

• Hopital Ambroise Pare — Boulogne-Billancourt, France (enrolling)
• Institut Curie — Paris, France (enrolling)
• Institut Curie — Saint-Cloud, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.